Jeffrey C. Mocny, PhD, of Abzena, and Anna McMahon, MS, of Cellares, discuss how biopharmaceutical risk-based standards accelerate innovation and speed-to-market by leveraging data for better patient outcomes and safety.
Anna McMahon
Advertisement
Anna McMahon is director of Regulatory Affairs at Cellares.
Articles by Anna McMahon
In this Drug Digest episode, Abzena’s vice president of Regulatory Strategy, Jeff Mocny, and Cellares’ director of Regulatory Affairs, Anna McMahon, examine how evolving regulatory and quality expectations are reshaping biopharmaceutical development and manufacturing.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Peptide Compounding Vote Raises New Questions for Drug Developers
2
PharmTech Weekly Roundup—July 24, 2026
3
What Jideytro's Approval Means for Drug Developers
4
Midyear 2026 Check-In: AI Investment Skipped Pharma's Costliest Operational Problem
5